Yubo International Biotech Reports Q2 2026 Financial Results with Increased Net Loss

Yubo International Biotech Limited reported its financial results for the second quarter of 2026, revealing a net loss of $268,721, compared to a loss of $249,722 in the same period of the previous year. For the first half of 2026, the company recorded a net loss of $563,747, slightly improved from a loss of $592,136 in the first half of 2025. The company did not generate any revenue from sales of products or services during both the three and six months ended June 30, 2026, maintaining the same trend as the previous year.

The company's total operating expenses for the second quarter of 2026 were $238,860, a decrease from $249,699 in the same quarter of 2025. The reduction in expenses was primarily attributed to lower employee compensation and occupancy costs. However, the overall financial position showed a decline, with total assets decreasing to $672,272 as of June 30, 2026, down from $847,094 at the end of 2025. Current liabilities increased significantly to $3,327,598, compared to $2,791,297 at the end of the previous year, indicating a growing financial strain.

In terms of strategic developments, Yubo International Biotech has been active in expanding its operations. On October 10, 2023, the company acquired Phoenix Club Bio-Medical Technology (Chengdu) Co., Ltd., which had minimal operations prior to the acquisition. This move is part of Yubo's strategy to enhance its product offerings and market presence. The company continues to explore opportunities for growth, including potential acquisitions and partnerships, although specific details on future product launches were not disclosed in the filing.

Operationally, Yubo's financial statements indicate a challenging environment, with no sales reported and a reliance on advances from prospective customers, which totaled $454,432 as of June 30, 2026. The company’s cash position improved slightly to $11,989 from $8,062 at the end of 2025, but it still faces significant liquidity challenges, as indicated by its negative working capital of $2,744,500. The company’s management has acknowledged the need for additional capital resources to sustain operations and has received a financial support commitment from its major shareholder to help meet liabilities over the next year.

Looking ahead, Yubo International Biotech's management has expressed concerns regarding its ability to continue as a going concern without securing additional funding. The company plans to pursue capital from management and significant shareholders, as well as seek third-party equity or debt financing. The ongoing challenges in generating revenue and the increasing liabilities underscore the critical need for strategic financial planning and operational adjustments to navigate the current market conditions effectively.